| Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 25 | Sale | 9.22 | 50,000 | 461,000 | 5,123,933 | Jan 26 05:23 PM | | Third Rock Ventures III, L.P. | 10% Owner | Jan 24 | Sale | 9.27 | 100,000 | 927,000 | 5,173,933 | Jan 26 05:23 PM | | Third Rock Ventures III, L.P. | 10% Owner | Jan 23 | Sale | 9.06 | 55,000 | 498,300 | 5,273,933 | Jan 24 06:20 PM | | Third Rock Ventures III, L.P. | 10% Owner | Jan 20 | Sale | 9.15 | 100,000 | 915,000 | 5,328,933 | Jan 24 06:20 PM | | Hesslein Robert W. | Senior VP & General Counsel | Jan 17 | Sale | 9.85 | 2,188 | 21,549 | 112,775 | Jan 19 04:57 PM | | Carter Todd Alfred | Chief Scientific Officer | Jan 17 | Sale | 9.85 | 1,106 | 10,892 | 35,088 | Jan 19 04:55 PM | | Swartz Robin | Chief Operating Officer | Jan 17 | Sale | 9.85 | 2,188 | 21,549 | 51,903 | Jan 19 04:53 PM | | EcoR1 Capital, LLC | 10% Owner | Jan 11 | Sale | 8.50 | 110,000 | 934,615 | 3,851,507 | Jan 11 06:26 PM | | EcoR1 Capital, LLC | 10% Owner | Jan 10 | Sale | 8.05 | 336,400 | 2,709,433 | 3,961,507 | Jan 11 06:26 PM | | EcoR1 Capital, LLC | 10% Owner | Jan 09 | Sale | 7.67 | 456,000 | 3,498,295 | 4,297,907 | Jan 11 06:26 PM | | Carter Todd Alfred | Chief Scientific Officer | Jan 06 | Sale | 6.41 | 388 | 2,487 | 36,194 | Jan 10 04:07 PM | | Third Rock Ventures III, L.P. | 10% Owner | Aug 25 | Sale | 6.22 | 200,000 | 1,244,000 | 5,428,933 | Aug 26 04:15 PM | | Third Rock Ventures III, L.P. | 10% Owner | Aug 24 | Sale | 6.09 | 149,972 | 913,329 | 5,628,933 | Aug 26 04:15 PM | | Third Rock Ventures III, L.P. | 10% Owner | Aug 16 | Sale | 6.04 | 128,456 | 775,874 | 5,778,905 | Aug 18 04:15 PM | | Third Rock Ventures III, L.P. | 10% Owner | Aug 15 | Sale | 6.04 | 135,808 | 820,280 | 5,907,361 | Aug 16 04:22 PM | | Third Rock Ventures III, L.P. | 10% Owner | Aug 12 | Sale | 6.12 | 348,007 | 2,129,803 | 6,043,169 | Aug 16 04:22 PM | | PIERCE GLENN | Director | Jul 14 | Sale | 6.70 | 9,512 | 63,730 | 16,788 | Jul 18 05:34 PM | | Higgins Michael J | Director | Jul 14 | Sale | 6.70 | 13,891 | 93,070 | 31,314 | Jul 18 05:32 PM | | EcoR1 Capital, LLC | 10% Owner | Jun 23 | Buy | 5.66 | 376,000 | 2,126,543 | 4,753,907 | Jun 23 05:21 PM | | EcoR1 Capital, LLC | 10% Owner | Jun 21 | Buy | 5.28 | 101,400 | 535,504 | 4,377,907 | Jun 23 05:21 PM | | Swartz Robin | Chief Operating Officer | Apr 04 | Sale | 8.25 | 1,527 | 12,598 | 52,060 | Apr 06 04:34 PM | | Hesslein Robert W. | Senior VP & General Counsel | Apr 04 | Sale | 8.25 | 2,786 | 22,984 | 114,963 | Apr 06 04:34 PM | | Swartz Robin | Chief Operating Officer | Mar 21 | Sale | 8.29 | 4,413 | 36,604 | 53,587 | Mar 23 06:40 PM | | Hesslein Robert W. | Senior VP & General Counsel | Mar 21 | Sale | 8.29 | 4,955 | 41,100 | 117,749 | Mar 23 06:39 PM | | Burek Julie | VP, Finance | Mar 21 | Sale | 8.29 | 2,649 | 21,972 | 52,458 | Mar 23 06:36 PM | | Burek Julie | VP, Finance | Feb 17 | Sale | 3.55 | 789 | 2,801 | 55,107 | Feb 22 04:35 PM | | Hesslein Robert W. | Senior VP & General Counsel | Feb 17 | Sale | 3.55 | 4,100 | 14,555 | 122,704 | Feb 22 04:37 PM | | Hesslein Robert W. | Senior VP & General Counsel | Feb 11 | Sale | 3.36 | 3,252 | 10,927 | 126,804 | Feb 15 04:42 PM | | Burek Julie | VP, Finance | Feb 11 | Sale | 3.36 | 361 | 1,213 | 55,896 | Feb 15 04:40 PM |
|
